AIMS: Schwannomas are common tumours that may be multiple in neurofibromatosis type 2, when they may be difficult to treat without significant morbidity using surgery and radiosurgery. Previous in vitro work has suggested that merlin loss is associated with activation of the JNK/JUN, PI3K/AKT and MEK/ERK pathways and that these pathways may be susceptible to pharmacological inhibition. The aim was to investigate the expression of proteins involved in these pathways in human schwannomas in situ. METHODS AND RESULTS: Immunohistochemistry using antibodies to AKT, pAKT, MEK, pMEK, ERK, pERK, JUN and pJUN was applied to 16 schwannomas (sporadic and NF2), and the results were compared with those seen in traumatic neuromas. Increased expression of pMEK, pERK and pJUN was seen in the schwannomas samples and of pAKT in schwannomas and controls. CONCLUSIONS: These findings provide further direct evidence for activation of the JNK/JUN, PI3K/AKT and MEK/ERK signalling pathways in schwannomas and support the development of therapeutic agents directed against these pathways for the treatment of this group of tumours.
AIMS: Schwannomas are common tumours that may be multiple in neurofibromatosis type 2, when they may be difficult to treat without significant morbidity using surgery and radiosurgery. Previous in vitro work has suggested that merlin loss is associated with activation of the JNK/JUN, PI3K/AKT and MEK/ERK pathways and that these pathways may be susceptible to pharmacological inhibition. The aim was to investigate the expression of proteins involved in these pathways in humanschwannomas in situ. METHODS AND RESULTS: Immunohistochemistry using antibodies to AKT, pAKT, MEK, pMEK, ERK, pERK, JUN and pJUN was applied to 16 schwannomas (sporadic and NF2), and the results were compared with those seen in traumatic neuromas. Increased expression of pMEK, pERK and pJUN was seen in the schwannomas samples and of pAKT in schwannomas and controls. CONCLUSIONS: These findings provide further direct evidence for activation of the JNK/JUN, PI3K/AKT and MEK/ERK signalling pathways in schwannomas and support the development of therapeutic agents directed against these pathways for the treatment of this group of tumours.
Authors: Alejandra M Petrilli; Marisa A Fuse; Mathew S Donnan; Marga Bott; Nicklaus A Sparrow; Daniel Tondera; Julia Huffziger; Corina Frenzel; C Siobhan Malany; Christophe J Echeverri; Layton Smith; Cristina Fernández-Valle Journal: Am J Transl Res Date: 2014-10-11 Impact factor: 4.060
Authors: Janet L Oblinger; Sarah S Burns; Jie Huang; Li Pan; Yulin Ren; Rulong Shen; A Douglas Kinghorn; D Bradley Welling; Long-Sheng Chang Journal: Exp Neurol Date: 2017-06-10 Impact factor: 5.330
Authors: Abraham Jacob; Janet Oblinger; Matthew L Bush; Victoria Brendel; Griffin Santarelli; Abhik R Chaudhury; Samuel Kulp; Krista M D La Perle; Ching-Shih Chen; Long-Sheng Chang; D Bradley Welling Journal: Laryngoscope Date: 2011-11-22 Impact factor: 3.325
Authors: Yuhao Shi; Saumya R Bollam; Shannon M White; Sean Z Laughlin; Garrett T Graham; Mandheer Wadhwa; Hengye Chen; Chan Nguyen; Jeremie Vitte; Marco Giovannini; Jeffery Toretsky; Chunling Yi Journal: Dev Cell Date: 2016-11-03 Impact factor: 12.270
Authors: Marisa A Fuse; Christine T Dinh; Jeremie Vitte; Joanna Kirkpatrick; Thomas Mindos; Stephani Klingeman Plati; Juan I Young; Jie Huang; Annemarie Carlstedt; Maria Clara Franco; Konstantin Brnjos; Jackson Nagamoto; Alejandra M Petrilli; Alicja J Copik; Julia N Soulakova; Olena Bracho; Denise Yan; Rahul Mittal; Rulong Shen; Fred F Telischi; Helen Morrison; Marco Giovannini; Xue-Zhong Liu; Long-Sheng Chang; Cristina Fernandez-Valle Journal: Neuro Oncol Date: 2019-03-18 Impact factor: 12.300